The global chitosan market reached a value of US$ 611 Million in 2018. Chitosan is a naturally occurring deacetylated chitin which is extracted from the hard outer-skeleton or shells of shrimps, crabs and lobsters, along with mushrooms and yeasts. It is primarily used as an ingredient in medicines for treating various conditions, such as kidney failure, obesity, anemia, high cholesterol levels, hyperphosphatemia, insomnia and Crohn’s disease. In the pharmaceutical manufacturing sector, chitosan is utilized in the development of edible films; as a filler in tablets; a carrier in controlled-release drugs and to improve the dissolvability of certain medicinal salts. Having antibacterial and antifungal properties, chitosan is extensively used as a natural antimicrobial agent in the cosmetics, agricultural and food industries.
The growing pharmaceutical industry, along with the increasing requirement for wastewater treatment across the globe represent the key factors driving the growth of the market. In the pharmaceutical industry, chitosan being a biomaterial with antibacterial and antimicrobial properties, is gaining demand in the production of biomedical and tissue regeneration devices, hemodialysis membranes and implant coatings for drug delivery systems. Furthermore, its demand is also increasing in the water treatment plants for eliminating impurities present in the industrial, municipal and commercial waste, including heavy minerals, phosphorous and oils. It is also used as a flocculating, coagulating and chelating agent, which is further acting as a major growth-inducing factor. Additionally, owing to its non-toxic nature, chitosan is increasingly being adopted as a food additive and dietary supplement. Other factors contributing to the market growth include various government policies aimed to improve the quality of surface, ground and drinking water, coupled with the enhanced research and development (R&D) to develop chitosan from non-aquatic sources. Looking forward, IMARC Group expects the market to reach a value of US$ 1,218 Million by 2024, registering a CAGR of around 12% during 2019-2024.
The report has also analysed the competitive landscape of the market with some of the key players being Primex EHF, Heppe Medical Chitosan, Advanced Biopolymers AS, Meron Biopolymers, Kitozyme, Golden-Shell Biochemical, FMC Corporation, Agratech, Axio Biosolutions, Marshall Marine Products, etc.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at